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them is an essential component of CER. The Atrial Fibrillation methods guidance
was developed in a unique process to improve the future quality of evidence with
a balance between internal validity and external generalizability.
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DRUG APPROVAL STRATEGIES IN GERMANY
Gissel C
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OBJECTIVES: The German legislator introduced early benefit assessments of al-
most all new drug approvals in 2011. Within one year after approval, the pharma-
ceuticalmanufacturer and the Statutory Health Insurance funds negotiate a rebate
based on the early benefit assessment. For each new drug, a common rebate for all
indications is negotiated. Therefore, themanufacturer needs to analyzewhether or
not to seek approval for each potential indication. We aim to analyze the manu-
facturer’s decision. METHODS: We develop a binary decision model to determine
profitability of each indication. Profitability is defined as a positive contribution to
the manufacturer’s global revenue. We apply our model to Ticagrelor as an exam-
ple. Ticagrelor was the first drug that was subject to an early benefit assessment.
The assessment is publicly available and delivers information for four indications.
RESULTS: The approval decision for a specific indication depends on five factors: 1)
Expected benefit as determined by the early benefit assessment; 2) Expected DDDs
in Germany; 3) Willingness for off-label use in the indication in Germany; 4) Ex-
pected DDDs globally; and 5) Impact of the German price on the mean global price.
CONCLUSIONS: The approval decision proves to be complex. Ticagrelor’s early
benefit assessment has shown the important role of the comparator used in the
assessment. The manufacturer named no trials to prove benefit over the adequate
comparators for STEMI (percutaneous coronary intervention) and STEMI (coronary
artery bypass grafting). Willingness for off-label use, however, is high, as currently
observed for Clopidogrel. For such a case, our model shows that it is profitable to
just seek approval for the indication with the greatest additional benefit (unstable
angina/NSTEMI). Based on the best indication, the manufacturer can negotiate a
smaller rebate. Additional revenue is generated if off-label prescriptions are com-
mon in other indications.
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WARNINGS: A CASE STUDY USING AN INTERRUPTED TIME SERIES ANALYSIS
OF THE MEDICARE DATABASE FOR 2006-2008
Oko-Osi H, Banahan BFI, West-Strum D, Bentley JP
University of Mississippi, University, MS, USA
OBJECTIVES: To evaluate the impact of Food and Drug Administration (FDA) safety
warning on the utilization rates of thiazolidinedione oral anti-diabetes medica-
tions using an interrupted time series analysis.METHODS: The analysis used data
from the five percent national sample of Medicare Part D beneficiaries. Beneficia-
ries were included if they were diabetic, continuously enrolled in Part D and had
filled a prescription for a thiazolidinedione medication at any time during the
period of January 2006 through December 2008. Beneficiaries were classified each
month into appropriate-use, at risk, and contraindicated groups based on the pres-
ence of certain comorbid conditions. Data were aggregated to monthly utilization
rates. Analyses examined the effects of the May 2007 FDA safety warnings about
the ongoing review of rosiglitazone’s potential to increase cardiovascular risks on
thiazolidinedione utilization rates for the different appropriateness of use catego-
ries using an interrupted time series consisting of 32 data points (13months before
and 19 months after the safety warning). RESULTS: There was an increasing trend
in the total utilization rates of thiazolidinediones before the safety warning. Sig-
nificant decline in drug utilization rates were observed at the end of the study
period for all patient groups on rosiglitazone (relative difference -74.78%, -79.93%,
and -90.21% in appropriate-use, at risk and contraindicated patient groups, respec-
tively). The intervention did not have significant immediate effects on the post-
intervention utilization rates of pioglitazone. However, after the intervention, a
general decline in utilization of thiazolidinediones, including pioglitazone, was
observed. CONCLUSIONS: The initial safety warning about rosiglitazone’s cardio-
vascular safety was effective in decreasing rosiglitazone’s utilization in the tar-
geted population and thus appeared to achieve the desired safety effects. The
safety warning, however, also had spillover effects by reducing utilization of drugs
in other patient cohorts not targeted by the warning.
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OBJECTIVES: Pharmaceutical expenditure is rapidly growing and accounts for
40-50 percent of total medical care expenditures. In order to contain drug expen-
diture growth effectively, we need to understand what the drivers are. This study
aims to answer the question by decomposing the pharmaceutical expenditure
changes into prices, volume, and product substitution effects.METHODS: By using
quarterly drug sales records from 2006-2011 of a large public hospital in Sichuan
province, we analyze the pharmaceutical expenditure changes for two therapeutic
groups: antibiotics (249 products molecules with 2491 records) and cardiovascu-
lar(130 products molecules with1668 records). After standardizing volume and
price recommended by DDD (WHO), a statistic index factor analysis is employed.
Specifically, Laspeyres price index (LPI) and chained LPI are employed to calculate
the price changes with and without entry and exit of products over time. We also
take a closer look at the substitution pattern, including shift among therapeutic
groups, shift between brand and generic drugs, and shift between old and new
drugs. RESULTS: Our results show that both antibiotics and cardiovascular drug
expenditures increased over 30% in the past 5 years. Interestingly, prices are con-
tinuously dropping and the volumes are slightly increasing for both antibiotics and
cardiovascular drugs. Relatively speaking, substitution effect plays the most im-
portant role in expenditure growth. Specifically, proportions of brand-name drugs,
new drugs, and more therapeutic advanced drugs are increasing over time.
CONCLUSIONS: Our study indicates that the key factor that contributes to the
expenditure growth is product substitution effect. Thus, price control policies may
not be an effective way to control the rapid pharmaceutical expenditure growth.
Instead, more attention should be paid on how to control the substitution shifts,
whichmay be caused by prescriber behavior and consumer demand. Further anal-
ysis should also be on the impact of substitution shift on quality of health care.
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OBJECTIVES: To assess the prevalence and determinants of pharmacotherapy in
patients with myocardial infarction. METHODS: The Medical Expenditure Panel
Survey (MEPS) data from 2004 to 2008 were used to conduct a retrospective cross-
sectional study. Study sample included adults  18 years with myocardial infarc-
tion. Pharmacotherapy was defined as the use of aspirin, beta-blockers, statins or
ACEI/ARB. Descriptive characteristics were used to describe the study sample and
utilization patterns. The predictors of pharmacotherapy use were modeled based
on the Andersen Behavior Model using logistic regression. The year variable and
the Charlson’s comorbidity index score (CCI) was also included in the analyses. A
p-value of 0.05was considered to be statistically significant. RESULTS:According to
theMEPS, 55% of the patients received ACEI/ARBs, 68% received beta-blockers, 64%
received statins and 75% received aspirin. Individuals who had a usual source of
healthcare were twice asmore likely to receive ACEI/ARBs (OR: 2.15; CI: 1.20 – 3.84).
Also, patients who were publicly insured (OR: 0.50; CI: 0.28 – 0.90), those who re-
sided in metropolitan region (OR: 0.69; CI: 0.50 – 0.95) and patients having a CCI
score of 2, 3 or 4 were less likely to receive ACEI/ARBs. Females (OR: 0.63; CI: 0.44 –
0.91), blacks (OR: 0.45; CI: 0.30 – 0.66) and individuals who had a CCI score of 10 (OR:
0.22; CI: 0.08 – 0.58) were less likely to receive beta-blockers. Also, as age increased,
the likelihood of taking beta-blockers (OR: 1.22; CI: 1.11 – 1.34) and aspirin (OR: 1.24;
CI: 1.11 – 1.39) increased. Patients who had a usual source of healthcare were 3
times as likely to receive statins (OR: 3.05; CI: 1.53 – 6.10). CONCLUSIONS: Analyses
of national level data revealed suboptimal utilization of evidence-based pharma-
cotherapy for management of myocardial infarction. Concerted efforts are needed
to optimize pharmacotherapy in patients with myocardial infarction.
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OBJECTIVES: Results from several clinical trials have showed that rhythm-control
drugs, which have serious adverse events, have no survival advantage over rate-
control drugs in patients with atrial fibrillation (AF). The objective of the study was
to determine 1) the trends in utilization for rate-control and rhythm-control drugs
from 2001 to 2009; and 2) if the utilization of rhythm-control drugs decreased over
time. METHODS: The physician’s-office and outpatient data components of the
National Ambulatory Medical Care Survey (NAMCS) from 2001 to 2009 were used.
Visits with AF were identified by ICD-9 diagnosis code, ‘427.31’. From these visits,
visits with mentions of rate-control drugs, beta blockers (e.g. metoprolol, propran-
olol, carvedilol, etc.) and non-dihydropyridine calcium channel blockers (vera-
pamil and diltiazem) and visits with mentions of rhythm-control drugs ( e.g. ami-
odarone, disopyramide, propafenone, etc.) were identified using drug codes
provided by NAMCS. Trends in utilization were calculated as total number of visits
with prescriptions divided by total number of visits with AF for each year.
RESULTS: From 2001 to 2009, visits with AF rose from 6.83 million to 11.56 million.
The prescription rate for rate-control drugs increased from 24.28% to 62.31% from
2001 to 2009. The prescription rate for rhythm-control drugs remained the same,
5.31% in 2001 and 5.14% in 2009. The prescription rate for any pharmacotherapy for
AF increased from 29.32% to 67.44% from 2001 to 2009. CONCLUSIONS: The utili-
zation of rhythm-control drugs remained constantwhile that of rate- control drugs
increased from 2001 to 2009. Previously, the treatment approach for AF was to
achieve normal sinus rhythm with rhythm-control drugs and direct current car-
dioversion, rather than use the rate-control drugs. Following the trials on rate-
control and rhythm-control drugs, the use of rate-control strategy increased.
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OBJECTIVES: To characterize the real-world profile of heart failure (HF) patients
with reduced ejection fraction (REF) and their treatment patterns in China.
METHODS: A retrospective chart review was conducted in 9 hospitals in 5 key
regions (Beijing, Shanghai, Wuhan, Chengdu, Guangzhou) to capture patient pro-
files and to evaluate treatment patterns in patients following hospitalization for
HF. Patients hospitalized for HF in 2005-2008 were identified. A total of 805 HF
subjects’ charts were selected and reviewed for health care treatment between
2000 and 2011. Data were collected from the first HF hospitalization until the last
date of data entry or death. RESULTS: A total of 460 patients with HF-REF and at
least one hospitalization were followed for an average of 2.86 years. Patients were
aged 61.814.12, and 65.9% were male. On average, HF-REF patients had 2.02.30
hospitalizations during follow-up. At the first hospitalization, severity was most
frequently New York Heart Association (NYHA) Class III in 46.4% of patients, fol-
lowed by Class IV in 27.1% and Class II in 26.0%. HF severity increased with subse-
quent hospitalizations. The most common etiologic/comorbid conditions were
idiopathic dilated cardiomyopathy (49.3%) followed by hypertension (42.2%), atrial
fibrillation (24.1%) and ischemic heart disease (20.2%). Median length of stay for the
first hospitalization was 10 days with the subsequent 3 hospitalizations ranging
between 8-9 days. The overall death rate during the follow-up period was 19.35%
with regional variance; 0% in Shanghai to 32% in Wuhan; however Shanghai sub-
jects had milder HF. The mean time to death was 747.0568.9 days from first
hospitalization for thosewho died (median: 779.0).CONCLUSIONS:This large chart
review provides a recent, real-world patient profile of HF-REF patients following
hospitalization for HF in China. Heart failure treatment presents a large burden to
the health care system in the 5 major regions in China, with some regional
variations.
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OBJECTIVES: Atrial fibrillation (AF), the most common sustained arrhythmia, con-
fers an increased risk of death in patients with myocardial infarction (MI). The
onset of AF in relation to MI differentially impacts survival, with AF developing
after MI corresponding to the worst survival. However, the impact of AF and its
timing on healthcare resource utilization after MI is unknown.METHODS: The risk
of hospitalization, emergency department (ED) visits, and outpatient office visits
associated with prior, early-onset (30 days post-MI) and late-onset (30 days
post-MI) AF was assessed among incident MI patients from 2002–2009 in the com-
munity. Andersen-Gill modeling was used to predict hospitalizations and ED visits
by AF category, whereas negative binomial regression was used for outpatient
visits. RESULTS: Of 1362 MI patients (mean age 6815, 57%men), 221 had prior AF,
134 developed early-onset AF, 96 developed late-onset AF, and 911 had no AF. Over
a mean of 3.7 years, 3335 hospitalizations, 4940 ED visits, and 70,632 outpatient
visits occurred. After adjustment, as compared to those without AF, patients with
prior and early-onset AF exhibited a 1.5-fold and 1.3-fold increased risk of hospi-
talization, respectively. In contrast, late-onset AF carried a 2.1-fold increased risk of
hospitalization. The corresponding hazard ratios for ED visits were 1.4, 1.2, and 1.7
for prior, early-onset, and late-onset AF, respectively. Surprisingly, the risk of out-
patient visits did not differ by the timing of AF, and only a 1.3-fold increased risk
was observed for late-onset AF.CONCLUSIONS:AmongpatientswithMI, the risk of
subsequent hospitalizations and ED visits differed markedly according to the tim-
ing of AF, with approximately twice the risk among those developing late-onset AF
compared to MI patients without AF. AF is an adverse prognostic indicator in MI
and these data underscore the importance of its management in MI patients.
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OBJECTIVES: To evaluate the profile of patients undergoing hip replacement (THR)
or knee replacement (TKR) surgery and the associated costs with surgery according
to public health care system (SUS) perspective. METHODS: A review of a govern-
ment administrative claims database (DATASUS) was conducted for patients who
underwent a THR or TKR procedure between January 2009 to March 2011. Data
regarding gender, age and mean costs per patients were analyzed for the entire
period and data for procedures costs were collected per year, as some of themwere
excluded from SUS procedure list. RESULTS: A total of 41,862 patients were iden-
tified at study period (12,476 for TKR and 29,386 THR). Average agewas 65,6 (SD 10,5)
for TKR and 64,1(SD 14,9) for THR, being women more frequently submitted to
surgery than men (71,7% vs 28,3% for TKR and 55,7% vs 44,3% for THR). Mean
hospitalizations costs per patient was $BRL4,203 (SD $BRL2,115) and $BRL4,130 (SD
$BRL2,145) for TKR and THR respectively. When comparing expenses according to
procedures groups, prostheses represented 76,9% and 76,8% of total costs in 2009
and 2010 respectively, followed by health care professionals. CONCLUSIONS:More
than 40,000 total arthroplasty surgeries were performed in SUS from January 2009
until March 2011, when THR accounted for approximately 70% of all cases. Mean
age for patients submitted to surgery were similar for both procedures, being
women more frequently undertaking surgery than man. When considering all
costs associated to arthroplasty, total expenses were similar in both groups. How-
ever, when compared with costs reported at the private system (described else-
where), expenses in SUS represents about 12%.
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OBJECTIVES: Acute heart failure (AHF) is a mounting problem worldwide, with
significant economic burden. Renal impairment is common among patients with
AHF but its full economic implications are unknown. The study aims to describe
and compare medical resource utilization and costs among AHF patients with and
without renal impairment.METHODS: Patients with1 hospitalization with a pri-
mary diagnosis of AHF continuously enrolled for 6 months of baseline period
prior to the first hospitalization (FH) were identified in the US MarketScan claims
database (2004-2008). History of renal impairmentwas identified using ICD-9 codes
at baseline or FH. Patients were observed for 12 months post FH or until insurance
disenrollment. Measured outcomes include inpatient resource utilization, hospital
length of stay (LOS) and costs. Rates of hospital re-admissions, outpatient visits
and costs were calculated per patient per month (PPPM). RESULTS: A total of 6396
AHF patients (mean age 73.6 years, 50.6% female) were studied; 1082 (17%) had
renal impairment. At FH, renal patients hadmore comorbidities, longer LOS (7.0 vs.
7.9 days), and similar costs ($15,820 vs. $15,467) compared to non-renal patients.
The average cost per re-hospitalization was $17,887 vs. $16,780 for renal vs. non-
renal patients, with average LOS of 7.9 and 6.5 days, respectively. Throughout the
study period, re-hospitalization, outpatient visit rates and costs PPPM were signif-
icantly (P0.05) higher among renal compared to non-renal patients, with highest
costs and rates observed within 3 months of FH ($2,480 vs. $1,421 total healthcare
cost PPPM; 0.063 vs. 0.024 re-hospitalization PPPM and; 1.406 vs. 1.051 outpatient
visits PPPM). CONCLUSIONS: AHF patients with renal impairment are resource
intensive and a costly subgroup of AHF population. Their increased use of outpa-
tient services despite having longer, more frequent hospitalizations suggest an
unmet need thus, new therapies that reduce re-hospitalizations may offer mean-
ingful cost savings and improved health outcomes.
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OBJECTIVES: As the primary care sector does not bear the direct costs of hospital-
ization, it may under-invest in prevention to avoid hospitalizations. This could
increase overall primary care spending if hospitalizations are associated with sub-
sequent increases in primary care resource use. The objectives of this studywere to
compare the number of primary care visits one year before and after a hospitaliza-
tion, within hospitalized patients, and between non-hospitalized and hospitalized
patients (post hospitalization). METHODS: Data on hospital and primary care re-
source use among hypertensive patients (17 years) were extracted from elec-
tronic patient journals from 1999 through 2007. Differences in number of visits
prior to and post hospitalization, and between hospitalized and non-hospitalized
patients, were assessed using standard statistical tests. Propensity-scorematching
was used to account for differences in observable characteristics.RESULTS:Among
10,196 patients, 4,692 patients were hospitalized and 5,504 were not hospitalized.
During the year prior to hospitalization, hospitalized patients had a significantly
lower (p0.0001) mean number (SD) of total visits than in the post-hospitalization
year: 4.58 (7.75) versus 6.91 (12.12). Non-hospitalized patients had significantly
fewer (p0.0414) visits than hospitalized patients (post-hospitalization): 4.46 (4.28)
versus 6.91 (12.12). Results were qualitatively similar for GP and nurse visits, in
different subgroups (e.g. age, diabetes), and in patients without prior cardiovascu-
lar disease or cancer. Also when comparing propensity-matched (e.g. gender, geo-
graphic region) hospitalized and non-hospitalized patients, results remained sim-
ilar. The number of visits demonstrated a rising trend prior to hospitalization and
peaked during the three months post hospitalization. After three months, the
number of visits decreased yet stabilized at a higher level than before
hospitalization.CONCLUSIONS:Weshow that hospitalizations are associatedwith
significant subsequent increases in primary care resource use. This suggests that
investing in treatments that prevent hospitalizations could potentially reduce
overall costs in primary care while improving patient health.
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OBJECTIVES: To determinemedical resource utilization and costs following hospi-
talization among elderly patients with chronic heart failure (HF). METHODS: Pa-
tients 65 years and older, with 1 hospitalization with a chronic HF diagnosis
(ICD-9 428.22, 428.32 or 428.42) were identified in the MarketScan® database be-
tween 2004 and 2008. Patients were observed starting 6 months prior to index
chronic HF hospitalization (IH) until disenrollment or end of data availability. Re-
source use and costs during IH and subsequent 4 HF re-hospitalizations were cal-
A130 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
